Robert G.  Shepler net worth and biography

Robert Shepler Biography and Net Worth

Director of Akoya Biosciences
Bob has served on Akoya Bioscience’s board since the company’s inception in 2015.  Bob was a founder and served as a Managing Director of Telegraph Hill Partners (THP), a growth equity/late-stage venture capital investment firm focused exclusively on healthcare related companies, since its founding in 2001 until August 2020 when he became Partner Emeritus.  Prior to THP, Bob was a principal in the investment firm of Mackowski & Shepler and an officer in the investment banking division of Merrill Lynch & Co.  In addition to Akoya Biosciences, Bob currently serves on the boards of Agena Biosciences, Inc. and Dynex Technologies, Inc.  Previously, Bob served on the boards of Kinetikos Medical (acquired by Integra), AcroMetrix, Inc. (acquired by Life Technologies), Aurora Discovery, Inc. (acquired by NEXUS Biosystems), Applied Precision (acquired by GE), LDR Holding Corporation (NASDAQ:LDRH), Endoscopic Technologies, Inc. (acquired by AtriCure), Sage Labs, Inc. (acquired by Horizon Discovery), Vidacare Corporation (acquired by Teleflex), ReloAction, Inc. (acquired by Hewitt Associates), Microinterventional Systems, Inc. (acquired by Medtronic), Reading Glass Company, Inc., One Body, Inc., R.D. Percy & Company, RareCyte, Inc. and was chairman of Genomics Solutions, Inc. (NASDAQ: GNSL).  He also was a board observer at Magstim, Inc. and Precision Nanosystems, Inc. (acquired by Danaher).  Bob received a BA from Duke University and an MBA from New York University.

How do I contact Robert G. Shepler?

The corporate mailing address for Mr. Shepler and other Akoya Biosciences executives is , , . Akoya Biosciences can also be reached via phone at 855-896-8401 and via email at [email protected]. Learn More on Robert G. Shepler's contact information.

Has Robert G. Shepler been buying or selling shares of Akoya Biosciences?

Robert G. Shepler has not been actively trading shares of Akoya Biosciences during the past quarter. Most recently, on Thursday, November 18th, Robert G. Shepler bought 35,000 shares of Akoya Biosciences stock. The stock was acquired at an average cost of $12.60 per share, with a total value of $441,000.00. Learn More on Robert G. Shepler's trading history.

Who are Akoya Biosciences' active insiders?

Akoya Biosciences' insider roster includes Garry Nolan (Director), Niro Ramachandran (Insider), and Robert Shepler (Director). Learn More on Akoya Biosciences' active insiders.

Are insiders buying or selling shares of Akoya Biosciences?

In the last twelve months, insiders at the sold shares 5 times. They sold a total of 37,500 shares worth more than $138,600.00. The most recent insider tranaction occured on June, 11th when CEO Brian Mckelligon sold 7,500 shares worth more than $15,600.00. Insiders at Akoya Biosciences own 7.3% of the company. Learn More about insider trades at Akoya Biosciences.

Information on this page was last updated on 6/11/2024.

Robert G. Shepler Insider Trading History at Akoya Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/18/2021Buy35,000$12.60$441,000.00View SEC Filing Icon  
See Full Table

Robert G. Shepler Buying and Selling Activity at Akoya Biosciences

This chart shows Robert G Shepler's buying and selling at Akoya Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Akoya Biosciences Company Overview

Akoya Biosciences logo
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Read More

Today's Range

Now: $2.19
Low: $2.13
High: $2.25

50 Day Range

MA: $2.88
Low: $2.09
High: $3.24

2 Week Range

Now: $2.19
Low: $1.88
High: $6.31

Volume

35,962 shs

Average Volume

225,245 shs

Market Capitalization

$108.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.34